Lixte Biotechnology Holdings, Inc. (LIXTW)

NASDAQ: LIXTW · Real-Time Price · USD · Warrants
0.2020
+0.0120 (6.32%)
Aug 29, 2025, 4:00 PM - Market closed
6.32%
Market Cap17.86M
Revenue (ttm)n/a
Net Income (ttm)-3.09M
Shares Out 4.56M
EPS (ttm)-1.27
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume5,142
Open0.1900
Previous Close0.1900
Day's Range0.1900 - 0.2270
52-Week Range0.0190 - 0.3800
Beta0.45
Analystsn/a
Price Targetn/a
Earnings DateAug 8, 2025

About LIXTW

Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company’s LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcin... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2005
Employees 2
Stock Exchange NASDAQ
Ticker Symbol LIXTW
Full Company Profile

News

There is no news available yet.